Tusk Therapeutics presents data on to its anti-CD25 programme at AACR Annual Meeting 2018

~ A first-in-class anti-CD25 Treg depleting antibody which enables Teff responses for optimal anti-cancer activity ~ London and Stevenage, UK – 18 April 2018:  Tusk Therapeutics, an immuno-oncology company focused on developing immune-modulating therapeutics by targeting immune cells in cancer, presented pre-clinical proof-of-concept data generated in collaboration with Cancer Research UK and University College London (UCL), relating to its anti-CD25 … Read More

Tusk Therapeutics to Present Data at AACR Annual Meeting 2018

London and Stevenage, UK – 28 March 2018: Tusk Therapeutics, an immuno-oncology company focused on developing immune-modulating therapeutics by targeting immune cells in cancer, announces today that it will deliver an oral presentation and three poster presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting taking place from 14th – 18th April 2018 at McCormick Place North/South, … Read More

BioCentury article: CD38 Hat Trick

This article is also available in pdf format. Tusk Therapeutics Ltd. thinks its anti-CD38 mAb could be best in class for solid tumors because it not only kills cancer cells and inhibits immunosuppressive cells, as its competitors do, but it also directly activates effector T cells. The CD38 space initially gained prominence based on the speedy development and commercial success of … Read More

Tusk Therapeutics awarded £2.5 million Grant from Innovate UK’s “Biomedical Catalyst Round 2 Late Stage”

Novel CD38 Targeting Cancer Immunotherapy Grant allows Tusk to accelerate its strongly differentiated anti-CD38 immunotherapy development program for treatment of solid cancers London and Stevenage, UK – 14 November 2017: Tusk Therapeutics is an immuno-oncology company with a focus on harnessing the power of the immune system to fight cancer through the development of novel immune modulating therapeutics.  Tusk today … Read More

Tusk Therapeutics appoints Matthew Hall as Chief Financial Officer

London and Stevenage, UK – 14 September 2017: Tusk Therapeutics, an immuno-oncology company, is pleased to announce the appointment of Matthew Hall as Chief Financial Officer. Matthew is a seasoned finance professional with over 20 years’ corporate finance experience in a number of leading organisations and fast growing companies.  Most recently Chief Financial Officer at Simbec-Orion Group, Matthew has extensive … Read More

UCL’s Cancer Immunology group publishes on the relevance of CD25 as a target in cancer

London and Stevenage, UK Tusk Therapeutics, an immuno-oncology company, today announces that its collaborators, Dr. Sergio Quezada and Professor Karl Peggs of the Cancer Immunology group at University College London (UCL), published work in Immunity, a peer-reviewed medical journal, on targeting CD25 with an optimised antibody for the treatment of cancer. The paper entitled, Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T … Read More

Cancer Research Technology, UCL, and Tusk Therapeutics join forces to develop cancer immunotherapies

​London and Stevenage, United Kingdom CANCER RESEARCH TECHNOLOGY, Cancer Research UK’s commercial arm, Tusk Therapeutics, an immuno-oncology company and UCL (University College London) have signed a licence and collaboration agreement to research, develop and commercialise an antibody-based therapeutic against a target that plays a key role in immune suppression in cancer. ​ Under the terms of the agreement, Tusk Therapeutics … Read More